Tag: plasma protein therapeutics market growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

#Plasma Protein Therapeutics Market Growth From $37.08 Billion In 2026 To $48.98 Billion By 2030 At A CAGR Of 7.2%#_x000D_

The plasma protein therapeutics market has experienced significant expansion in recent years. Its valuation is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, at a compound annual growth rate (CAGR) of 6.9%. This historical growth can be ascribed to factors such as the increasing prevalence of primary immunodeficiency disorder, the rising demand for immunoglobulin therapies, a constrained plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies._x000D_

_x000D_

The plasma protein therapeutics market is projected to experience robust expansion over the coming years. It will grow to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth is driven by factors such as an increase in recombinant albumin and coagulation factors, the broader adoption of subcutaneous administration techniques, rising healthcare spending in developing economies, innovations in precision medicine, and a surge in public-private partnerships for collecting plasma. Key trends expected during this period involve the creation of personalized plasma protein therapies, the growth in recombinant protein manufacturing, a greater embrace of subcutaneous administration, heightened understanding of uncommon blood conditions, and improvements in supply chain and cold chain management._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=9213&type=smp&name=Plasma%20Protein%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Plasma Protein Therapeutics Market Growth Factors Behind Sustained Expansion#_x000D_

The expanding occurrence of autoimmune disorders is anticipated to stimulate the growth of the plasma protein therapeutics market in the future. An autoimmune disorder describes a state where the body’s immune system wrongly attacks and harms its own healthy cells. Therapeutic plasma exchange is employed to manage these autoimmune diseases, which manifest when the body mistakes a part of itself as foreign and produces proteins, known as autoantibodies, that target the misidentified body part. For instance, in May 2023, research conducted by the University of Glasgow, a UK-based public university, involving 22 million people, discovered that autoimmune disorders impact about 10% of the UK’s population, a figure higher than previous estimates from 2022. Consequently, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics market going forward._x000D_

_x000D_

#Plasma Protein Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_

The plasma protein therapeutics market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products_x000D_

2) By Route Of Administration: Intravenous, Subcutaneous_x000D_

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications _x000D_

_x000D_

Subsegments:_x000D_

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) _x000D_

2) By Albumin: Human Serum Albumin, Recombinant Albumin _x000D_

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates_x000D_

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors _x000D_

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates _x000D_

_x000D_

#Plasma Protein Therapeutics Market Industry Trends Fueling Future Revenue Growth#_x000D_

Leading companies in the plasma protein therapeutics market are concentrating on developing innovative solutions, such as lyophilized plasma formulations, to fulfill the increasing need for portable, stable, and quick-to-use blood products in emergency and pre-hospital medical environments. These freeze-dried plasma products offer an extended shelf life, simpler storage, and faster reconstitution compared to conventional frozen plasma, making them highly suitable for trauma, emergency medicine, and field settings. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient pre-hospital transfusion, providing rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports the effective management of trauma and bleeding emergencies, showcasing Octapharma’s dedication to advancing patient care through innovative plasma-based therapies._x000D_

_x000D_

#Plasma Protein Therapeutics Market Leading Players And Competitive Positioning#_x000D_

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG _x000D_

_x000D_

#View The Full Plasma Protein Therapeutics Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Plasma Protein Therapeutics Market Regional Analysis And Top Geography#_x000D_

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Plasma Protein Therapeutics Market Size, Value And Growth Trends Through 2030

The plasma protein therapeutics market has experienced notable expansion in recent years. Valued at $34.68 billion in 2025, it is projected to reach $37.09 billion by 2026, reflecting a compound annual growth rate (CAGR) of 6.9%. This historic growth has been driven by factors such as a higher incidence of primary immunodeficiency disorders, increased reliance on immunoglobulin therapies, constraints within plasma donation infrastructure, improvements in protein purification techniques, and regulatory endorsements for plasma-derived products.

The plasma protein therapeutics market is projected to experience robust expansion over the coming years, reaching an estimated $48.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is fueled by the rising demand for recombinant albumin and coagulation factors, the broader implementation of subcutaneous delivery methods, increased healthcare spending in developing economies, progress in precision medicine technologies, and a surge in public-private partnerships focused on plasma collection. Key developments shaping this period include the advancement of personalized plasma protein therapies, the growing production of recombinant proteins, the wider use of subcutaneous administration, heightened awareness regarding rare blood disorders, and improvements in supply chain and cold chain management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Plasma Protein Therapeutics Market Industry Drivers: What Is Driving Revenue Growth?

The rising occurrence of autoimmune conditions is anticipated to drive forward the expansion of the plasma protein therapeutics market. An autoimmune disorder arises when the immune system mistakenly targets and damages the body’s own healthy cells. Therapeutic plasma exchange serves as a treatment for these conditions, which occur when the body incorrectly identifies a part of itself as foreign and generates proteins, called autoantibodies, that attack that misidentified area. A study conducted in May 2023 by the University of Glasgow, a public university in the UK, analyzed data from 22 million people and revealed that autoimmune disorders impact roughly 10% of the UK population, surpassing earlier estimates from 2022. Consequently, the growing incidence of autoimmune diseases is fueling the market’s growth for plasma protein therapeutics.

Plasma Protein Therapeutics Market Segment Analysis: What Are The Major Market Categories?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Plasma Protein Therapeutics Market Growth Trends: What Is Influencing The Future Outlook?

Key players in the plasma protein therapeutics industry are placing significant emphasis on developing novel offerings, including lyophilized plasma formulations, in order to address the increasing need for portable, stable, and quickly deployable blood products in emergency and pre-hospital care environments. These freeze-dried plasma products provide extended shelf life, simplified storage requirements, and faster reconstitution when compared to conventional frozen plasma, making them exceptionally appropriate for trauma care, emergency medicine, and fieldwork settings. For example, in October 2023, Octapharma AG, a Swiss pharmaceutical company, secured approval from European health regulators for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient transfusion prior to hospital arrival, delivering rapid usability, easier handling, and enhanced stability in critical care scenarios. The product supports efficient treatment of trauma and bleeding emergencies, underscoring Octapharma’s dedication to improving patient outcomes through innovative plasma-derived therapies.

Plasma Protein Therapeutics Market Leading Companies Driving Competitive Growth

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Access The Complete Plasma Protein Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Plasma Protein Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Plasma Protein Therapeutics Market Become By 2030 Compared To 2026?

The plasma protein therapeutics market size has shown significant growth in recent years. It is anticipated to expand from $34.68 billion in 2025 to $37.09 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.9%. The increase during the historical period can be ascribed to the growing incidence of primary immunodeficiency disorder, an escalating need for immunoglobulin therapies, a constrained plasma donation infrastructure, developments in protein purification technologies, and regulatory clearances for plasma-derived treatments.

The plasma protein therapeutics market size is anticipated to demonstrate robust expansion over the next few years, with projections indicating growth to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. This expected increase during the forecast period can be attributed to the rise in recombinant albumin and coagulation factors, the proliferation of subcutaneous administration methods, escalating healthcare spending in developing markets, advancements in precision medicine technology, and an increase in public-private collaborations for plasma collection. Significant trends foreseen in this period include the evolution of personalized plasma protein therapy, an increase in recombinant protein production, wider acceptance of subcutaneous administration, growing recognition of rare blood disorders, and improved supply chain and cold chain logistics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

What Core Drivers Are Transforming The Plasma Protein Therapeutics Market?

The escalating occurrence of autoimmune conditions is anticipated to fuel expansion within the plasma protein therapeutics market moving forward. An autoimmune disorder is characterized by the body’s immune system mistakenly attacking and eliminating its own healthy cells. Therapeutic plasma exchange serves as a treatment for autoimmune diseases, which arise when the body perceives its own components as foreign, leading to the generation of proteins (known as autoantibodies) that target these misidentified body parts. For instance, in May 2023, research conducted by the University of Glasgow, a UK-based public university, involving 22 million individuals, revealed that autoimmune disorders impact approximately 10% of the UK’s populace, surpassing prior forecasts from 2022. Consequently, the rising incidence of autoimmune disorders is a key factor propelling the growth of the plasma protein therapeutics market in the future.

What Are The Major Segment Categories Within The Plasma Protein Therapeutics Market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

What Trends Are Affecting The Growth Of The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are focusing on developing innovative solutions, such as lyophilized plasma formulations, to meet the rising demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that offer longer shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma, making them highly suitable for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, received approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation enables convenient pre-hospital transfusion, offering rapid availability, simplified handling, and improved stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to advancing patient care through innovative plasma-based therapies.

Which Organizations Are Operating Within The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Access The Complete Plasma Protein Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Is The Dominant Market In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Plasma Protein Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Plasma Protein Therapeutics Market Compare Between 2026 And 2030?

The plasma protein therapeutics market has robustly expanded in recent years. Forecasts indicate it will enlarge from $34.68 billion in 2025 to reach $37.09 billion in 2026, registering a compound annual growth rate (CAGR) of 6.9%. The historical expansion of this market stems from several factors, including the increasing prevalence of primary immunodeficiency disorder, rising demand for immunoglobulin therapies, limited plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market size is anticipated to undergo significant growth in the coming years, with expectations to reach $48.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This projected expansion during the forecast period is primarily attributed to the rise in recombinant albumin and coagulation factors, the increasing availability of subcutaneous administration methods, growing healthcare expenditure in emerging economies, technological innovations within precision medicine, and an uptick in public-private collaborations for plasma collection. Prominent trends throughout this period are expected to include the development of personalized plasma protein therapies, an increase in recombinant protein production, wider acceptance of subcutaneous administration, rising awareness of rare blood disorders, and improved supply chain along with cold chain logistics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Strong Drivers Are Impacting The Plasma Protein Therapeutics Market Growth?

The increasing incidence of autoimmune disorders is projected to fuel the expansion of the plasma protein therapeutics market. An autoimmune disorder manifests when the body’s immune system erroneously attacks and destroys its own healthy cells. Therapeutic plasma exchange is employed to treat these autoimmune conditions, which arise when the body misidentifies a part of itself as alien and generates proteins known as autoantibodies to attack that misidentified component. For instance, in May 2023, a study conducted by the University of Glasgow, a UK-based public university, involving 22 million people, determined that autoimmune disorders affect about 10% of the UK’s population, exceeding earlier estimates from 2022. This increasing prevalence of autoimmune disorders is, therefore, driving the growth of the plasma protein therapeutics market going forward.

How Is The Plasma Protein Therapeutics Market Broken Down By Segment Categories?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Shaping Growth In The Plasma Protein Therapeutics Market?

Leading companies operating within the plasma protein therapeutics market are focusing on developing innovative solutions, such as lyophilized plasma formulations, to satisfy the growing demand for portable, stable, and rapidly usable blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that provide an extended shelf life, simpler storage, and quicker reconstitution when compared to traditional frozen plasma, rendering them highly appropriate for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a pharmaceutical company based in Switzerland, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation allows for convenient pre-hospital transfusion, offering rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports the effective management of trauma and bleeding emergencies, showcasing Octapharma’s dedication to advancing patient care through innovative plasma-based therapies.

Which Players Are Present In The Plasma Protein Therapeutics Market Space?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Get The Full Plasma Protein Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Dominates The Plasma Protein Therapeutics Market By Market Share?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Plasma Protein Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Plasma Protein Therapeutics Market Between 2026 And 2030?

The plasma protein therapeutics market size has demonstrated significant expansion in recent years. It is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. The historical growth in this market stems from factors such as the increasing prevalence of primary immunodeficiency disorder, a rising demand for immunoglobulin therapies, the limited plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market is anticipated to demonstrate robust expansion over the next few years. It is projected to achieve a valuation of $48.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth can be attributed to several factors, including the increased availability of recombinant albumin and coagulation factors, the proliferation of subcutaneous administration methods, rising healthcare expenditure in emerging economies, advancements in precision medicine technologies, and a rise in public-private collaborations for plasma collection. Prominent trends expected during this forecast period include the development of personalized plasma protein therapies, the expansion of recombinant protein production capabilities, an increase in the adoption of subcutaneous administration, growing public awareness of rare blood disorders, and enhancements in supply chain and cold chain logistics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Plasma Protein Therapeutics Market?

The increasing prevalence of autoimmune disorders is projected to fuel the expansion of the plasma protein therapeutics market moving forward. An autoimmune disorder is a condition that develops when the body’s immune system mistakenly attacks and eradicates healthy body cells. Therapeutic plasma exchange is employed to manage autoimmune diseases, which arise when the body incorrectly identifies a part of itself as alien and subsequently produces proteins, known as autoantibodies, that target the misidentified body part. For instance, in May 2023, a study carried out by the University of Glasgow, a UK-based public university, involving 22 million people, indicated that autoimmune disorders impact approximately 10% of the UK’s population, surpassing earlier estimates from 2022. Therefore, the rising incidence of autoimmune disorders is driving the growth of the plasma protein therapeutics market in the future.

Which Market Segments Are Examined In The Plasma Protein Therapeutics Market Study?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Influencing The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are concentrating on developing innovative solutions, such as lyophilized plasma formulations, to meet the increasing demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that provide a longer shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma, making them highly appropriate for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient pre-hospital transfusion, offering rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to improving patient care through innovative plasma-based therapies.

Who Are The Primary Competitors In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Read the full plasma protein therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

What Are The Leading Geographic Regions In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Protein Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Plasma Protein Therapeutics Market Between 2026 And 2030?

The plasma protein therapeutics market size has demonstrated significant expansion in recent years. It is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. The historical growth in this market stems from factors such as the increasing prevalence of primary immunodeficiency disorder, a rising demand for immunoglobulin therapies, the limited plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market is anticipated to demonstrate robust expansion over the next few years. It is projected to achieve a valuation of $48.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth can be attributed to several factors, including the increased availability of recombinant albumin and coagulation factors, the proliferation of subcutaneous administration methods, rising healthcare expenditure in emerging economies, advancements in precision medicine technologies, and a rise in public-private collaborations for plasma collection. Prominent trends expected during this forecast period include the development of personalized plasma protein therapies, the expansion of recombinant protein production capabilities, an increase in the adoption of subcutaneous administration, growing public awareness of rare blood disorders, and enhancements in supply chain and cold chain logistics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Plasma Protein Therapeutics Market?

The increasing prevalence of autoimmune disorders is projected to fuel the expansion of the plasma protein therapeutics market moving forward. An autoimmune disorder is a condition that develops when the body’s immune system mistakenly attacks and eradicates healthy body cells. Therapeutic plasma exchange is employed to manage autoimmune diseases, which arise when the body incorrectly identifies a part of itself as alien and subsequently produces proteins, known as autoantibodies, that target the misidentified body part. For instance, in May 2023, a study carried out by the University of Glasgow, a UK-based public university, involving 22 million people, indicated that autoimmune disorders impact approximately 10% of the UK’s population, surpassing earlier estimates from 2022. Therefore, the rising incidence of autoimmune disorders is driving the growth of the plasma protein therapeutics market in the future.

Which Market Segments Are Examined In The Plasma Protein Therapeutics Market Study?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Influencing The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are concentrating on developing innovative solutions, such as lyophilized plasma formulations, to meet the increasing demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that provide a longer shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma, making them highly appropriate for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient pre-hospital transfusion, offering rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to improving patient care through innovative plasma-based therapies.

Who Are The Primary Competitors In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Read the full plasma protein therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

What Are The Leading Geographic Regions In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Protein Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Plasma Protein Therapeutics Market Between 2026 And 2030?

The plasma protein therapeutics market size has demonstrated significant expansion in recent years. It is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. The historical growth in this market stems from factors such as the increasing prevalence of primary immunodeficiency disorder, a rising demand for immunoglobulin therapies, the limited plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market is anticipated to demonstrate robust expansion over the next few years. It is projected to achieve a valuation of $48.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth can be attributed to several factors, including the increased availability of recombinant albumin and coagulation factors, the proliferation of subcutaneous administration methods, rising healthcare expenditure in emerging economies, advancements in precision medicine technologies, and a rise in public-private collaborations for plasma collection. Prominent trends expected during this forecast period include the development of personalized plasma protein therapies, the expansion of recombinant protein production capabilities, an increase in the adoption of subcutaneous administration, growing public awareness of rare blood disorders, and enhancements in supply chain and cold chain logistics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Plasma Protein Therapeutics Market?

The increasing prevalence of autoimmune disorders is projected to fuel the expansion of the plasma protein therapeutics market moving forward. An autoimmune disorder is a condition that develops when the body’s immune system mistakenly attacks and eradicates healthy body cells. Therapeutic plasma exchange is employed to manage autoimmune diseases, which arise when the body incorrectly identifies a part of itself as alien and subsequently produces proteins, known as autoantibodies, that target the misidentified body part. For instance, in May 2023, a study carried out by the University of Glasgow, a UK-based public university, involving 22 million people, indicated that autoimmune disorders impact approximately 10% of the UK’s population, surpassing earlier estimates from 2022. Therefore, the rising incidence of autoimmune disorders is driving the growth of the plasma protein therapeutics market in the future.

Which Market Segments Are Examined In The Plasma Protein Therapeutics Market Study?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Influencing The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are concentrating on developing innovative solutions, such as lyophilized plasma formulations, to meet the increasing demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that provide a longer shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma, making them highly appropriate for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient pre-hospital transfusion, offering rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to improving patient care through innovative plasma-based therapies.

Who Are The Primary Competitors In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Read the full plasma protein therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

What Are The Leading Geographic Regions In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Protein Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma protein therapeutics market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Plasma Protein Therapeutics Market expected to grow between 2026 and 2030?

The plasma protein therapeutics market has demonstrated substantial growth in recent years. Its valuation is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion over the historic period is largely attributable to the increasing prevalence of primary immunodeficiency disorder, the rising demand for immunoglobulin therapies, the limited plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market is projected to experience substantial expansion in the coming years, reaching $48.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is driven by factors such as the rise in recombinant albumin and coagulation factor production, the broader adoption of subcutaneous administration techniques, escalating healthcare spending in developing economies, innovations in precision medicine, and increased partnerships between public and private entities for plasma collection. Key developments expected over the forecast horizon encompass the creation of personalized plasma protein therapies, an increase in recombinant protein manufacturing, wider acceptance of subcutaneous administration, a heightened understanding of rare blood conditions, and improvements in supply chain and cold chain management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Drivers Are Influencing Market Acceleration In The Plasma Protein Therapeutics Market?

The expanding occurrence of autoimmune conditions is projected to drive the expansion of the plasma protein therapeutics market in the future. Such a disorder arises when the body’s immune system mistakenly targets and damages its own healthy cells. Therapeutic plasma exchange serves as a treatment for autoimmune diseases, which develop when the body incorrectly perceives its own components as foreign and generates proteins, termed autoantibodies, that subsequently assault those misidentified body parts. For example, research performed by the University of Glasgow, a public university located in the UK, published in May 2023 and involving 22 million individuals, revealed that roughly 10% of the UK’s population is affected by autoimmune disorders, a figure higher than prior estimations from 2022. Consequently, the rising occurrence of autoimmune conditions is fueling the expansion of the plasma protein therapeutics market moving ahead.

What Segments Are Identified Within The Structure Of The Plasma Protein Therapeutics Market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Influencing The Development Of The Plasma Protein Therapeutics Market?

Leading companies operating within the plasma protein therapeutics market are concentrating on developing novel solutions, such as lyophilized plasma formulations, to satisfy the growing requirement for blood products that are portable, stable, and quick to use in emergency and pre-hospital care environments. Lyophilized plasma products are freeze-dried preparations that offer an extended shelf life, simplified storage, and faster reconstitution compared to traditional frozen plasma, rendering them highly appropriate for trauma, emergency medicine, and field settings. For instance, in October 2023, Octapharma AG, a pharmaceutical company based in Switzerland, obtained approval from European medical authorities for the lyophilized version of its octaplasLG product. This sophisticated formulation allows for convenient pre-hospital transfusion, providing rapid accessibility, straightforward handling, and improved stability for critical care situations. The product aids in the effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to advancing patient care through innovative plasma-based therapies.

Which Key Players Are Driving Competition In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Is Projected To Lead The Plasma Protein Therapeutics Market During The Forecast Period?

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Plasma Protein Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2026, By The Business Research Company

Plasma Protein Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Therapeutic Plasma Exchange Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma protein therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Plasma Protein Therapeutics Market In The Period 2029-2034?

The plasma protein therapeutics market size has exhibited strong growth in recent years. This market is set to expand from $32.22 billion in 2024 to $34.68 billion in 2025, progressing at a compound annual growth rate (CAGR) of 7.6%. The expansion observed historically can be attributed to factors such as the increasing prevalence of rare diseases, a growing aging population, the global supply of blood plasma, a rise in hemophilia cases, enhancements in diagnosis, and a supportive regulatory environment.

The plasma protein therapeutics market is projected to experience robust expansion over the coming years. This market is forecast to reach $45.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.1%. Key drivers for this growth during the forecast period include advancements in gene therapy, a rise in healthcare spending, a broader range of indications, the adoption of precision medicine approaches, and various patient access programs. Significant trends anticipated in the forecast period encompass technological innovations, the integration of telemedicine, advancements in plasma fractionation technology, the creation of next-generation therapies, the embracing of recombinant therapies, and strategies centered around personalized medicine.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

What Strategic Drivers Are Accelerating The Plasma Protein Therapeutics Market Expansion?

The growing occurrence of autoimmune disorders is anticipated to boost the expansion of the plasma protein therapeutics market in the coming years. An autoimmune disorder is a medical state where the body’s immune system mistakenly targets and eradicates healthy body cells. Therapeutic plasma exchange serves as a treatment for autoimmune conditions, which arise when the body incorrectly identifies parts of itself as foreign, subsequently generating proteins called autoantibodies that then attack those misidentified body parts. For instance, a May 2023 study by the University of Glasgow, a UK-based public university, involving 22 million people, discovered that autoimmune disorders impact approximately 10% of the UK’s population, surpassing previous estimates. Hence, the escalating prevalence of autoimmune disorders is a key driver for the plasma protein therapeutics market’s growth moving forward.

What Is The Detailed Segment Distribution Of The Plasma Protein Therapeutics Market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

How Are Global Trends Impacting The Development Of The Plasma Protein Therapeutics Market?

Product innovation is emerging as a significant trend in the plasma protein therapeutic gaining market. Leading companies operating in the plasma protein therapeutic sector are focusing on developing innovative products to gain a competitive advantage. For instance, in October 2023, Octapharma AG, a Switzerland-based company, received approval from European medical authorities for the lyophilized version of its widely recognized product, octaplasLG. This advanced formulation is designed for pre-hospital transfusion, providing healthcare professionals with a convenient and effective option for managing patients in critical situations. The approval underscores Octapharma’s commitment to enhancing patient care through innovative solutions in the field of blood products.

Who Are The Major Stakeholders Operating In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma protein therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Plasma Protein Therapeutics Market In The Period 2029-2034?

The plasma protein therapeutics market size has exhibited strong growth in recent years. This market is set to expand from $32.22 billion in 2024 to $34.68 billion in 2025, progressing at a compound annual growth rate (CAGR) of 7.6%. The expansion observed historically can be attributed to factors such as the increasing prevalence of rare diseases, a growing aging population, the global supply of blood plasma, a rise in hemophilia cases, enhancements in diagnosis, and a supportive regulatory environment.

The plasma protein therapeutics market is projected to experience robust expansion over the coming years. This market is forecast to reach $45.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.1%. Key drivers for this growth during the forecast period include advancements in gene therapy, a rise in healthcare spending, a broader range of indications, the adoption of precision medicine approaches, and various patient access programs. Significant trends anticipated in the forecast period encompass technological innovations, the integration of telemedicine, advancements in plasma fractionation technology, the creation of next-generation therapies, the embracing of recombinant therapies, and strategies centered around personalized medicine.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

What Strategic Drivers Are Accelerating The Plasma Protein Therapeutics Market Expansion?

The growing occurrence of autoimmune disorders is anticipated to boost the expansion of the plasma protein therapeutics market in the coming years. An autoimmune disorder is a medical state where the body’s immune system mistakenly targets and eradicates healthy body cells. Therapeutic plasma exchange serves as a treatment for autoimmune conditions, which arise when the body incorrectly identifies parts of itself as foreign, subsequently generating proteins called autoantibodies that then attack those misidentified body parts. For instance, a May 2023 study by the University of Glasgow, a UK-based public university, involving 22 million people, discovered that autoimmune disorders impact approximately 10% of the UK’s population, surpassing previous estimates. Hence, the escalating prevalence of autoimmune disorders is a key driver for the plasma protein therapeutics market’s growth moving forward.

What Is The Detailed Segment Distribution Of The Plasma Protein Therapeutics Market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

How Are Global Trends Impacting The Development Of The Plasma Protein Therapeutics Market?

Product innovation is emerging as a significant trend in the plasma protein therapeutic gaining market. Leading companies operating in the plasma protein therapeutic sector are focusing on developing innovative products to gain a competitive advantage. For instance, in October 2023, Octapharma AG, a Switzerland-based company, received approval from European medical authorities for the lyophilized version of its widely recognized product, octaplasLG. This advanced formulation is designed for pre-hospital transfusion, providing healthcare professionals with a convenient and effective option for managing patients in critical situations. The approval underscores Octapharma’s commitment to enhancing patient care through innovative solutions in the field of blood products.

Who Are The Major Stakeholders Operating In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model